DYNAMIC trial data spark Twitter talk about ‘future of patient risk stratification’

The potential for ctDNA-guided management to reduce adjuvant chemotherapy by half without compromising recurrence-free survival sparked interest on social media after a presentation at the ASCO Annual Meeting.Fresh off a presentation by Jeanne Tie, MD, MBChB, FRACP, on the DYNAMIC trial, Healio and Creation Healthcare, a digital insights company, analyzed health care provider sentiments on the results.Paolo Tarantino, MD (@PTarantinoMD). June 4, 2022. The MRD revolution has started. In this trial (n=455), stage II CRC pts were randomized to standard management or ctDNA-guided (no adj chemo ifRead More

Related Articles

2019 Telehealth Bill

In 2019, Florida passed the Telehealth Bill which establishes standards of practice for telehealth services, including patient evaluations, record-keeping, and controlled substances prescribing. The bill…